TCG Crossover Management
Latest statistics and disclosures from TCG Crossover Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, COGT, CGON, TNGX, CNTA, and represent 50.97% of TCG Crossover Management's stock portfolio.
- Added to shares of these 10 stocks: GLUE (+$73M), BHVN (+$52M), IMVT (+$42M), TNGX (+$37M), ADCT (+$35M), RAPT (+$32M), CNTA (+$29M), SYRE (+$26M), JANX (+$25M), ALEC (+$16M).
- Started 8 new stock positions in Athira Pharma, GLUE, ALEC, MAZE, MIRM, IMVT, JANX, BHVN.
- Reduced shares in these 10 stocks: TRML (-$63M), UPB (-$37M), COGT (-$33M), IRON (-$31M), Astria Therapeutics (-$20M), GPCR (-$9.9M), ADVM (-$7.6M), AGIO (-$6.8M), PEPG (-$5.5M), OCUL.
- Sold out of its positions in ADVM, Astria Therapeutics, IRON, PEPG, TRML.
- TCG Crossover Management was a net buyer of stock by $212M.
- TCG Crossover Management has $3.0B in assets under management (AUM), dropping by 48.64%.
- Central Index Key (CIK): 0001839948
Tip: Access up to 7 years of quarterly data
Positions held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 43 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa American Depositary Shares Adrs (ABVX) | 31.7 | $959M | 7.1M | 134.85 |
|
|
| Cogent Biosciences Comm (COGT) | 6.9 | $208M | -13% | 5.9M | 35.52 |
|
| Cg Oncology Comm (CGON) | 5.0 | $152M | 3.7M | 41.52 |
|
|
| Tango Therapeutics Comm (TNGX) | 3.7 | $113M | +49% | 13M | 8.86 |
|
| Centessa Pharmaceuticals Adrs (CNTA) | 3.5 | $107M | +36% | 4.3M | 25.01 |
|
| Dyne Therapeutics Comm (DYN) | 3.0 | $90M | 4.6M | 19.56 |
|
|
| Rapt Therapeutics Comm (RAPT) | 2.9 | $88M | +57% | 2.6M | 33.87 |
|
| Tyra Biosciences Comm (TYRA) | 2.5 | $76M | 2.9M | 26.29 |
|
|
| Amylyx Pharmaceuticals Comm (AMLX) | 2.5 | $75M | 6.2M | 12.08 |
|
|
| Savara Comm (SVRA) | 2.5 | $75M | 12M | 6.03 |
|
|
| Monte Rosa Therapeutics Comm (GLUE) | 2.4 | $73M | NEW | 4.6M | 15.68 |
|
| Ocular Therapeutix Comm (OCUL) | 2.3 | $70M | -6% | 5.7M | 12.14 |
|
| Dianthus Therapeutics Comm (DNTH) | 2.3 | $69M | 1.7M | 41.21 |
|
|
| Eyepoint Pharmaceuticals Comm (EYPT) | 2.2 | $65M | 3.6M | 18.27 |
|
|
| Structure Therapeutics Adrs (GPCR) | 2.1 | $64M | -13% | 921k | 69.55 |
|
| Spyre Therapeutics Comm (SYRE) | 2.1 | $62M | +72% | 1.9M | 32.76 |
|
| Fulcrum Therapeutics Comm (FULC) | 2.0 | $59M | 5.3M | 11.31 |
|
|
| Liquidia Technologies Comm (LQDA) | 2.0 | $59M | 1.7M | 34.49 |
|
|
| Biohaven Comm (BHVN) | 1.7 | $52M | NEW | 4.6M | 11.29 |
|
| Immunovant Comm (IMVT) | 1.4 | $42M | NEW | 1.7M | 25.42 |
|
| Kodiak Sciences Comm (KOD) | 1.3 | $40M | +26% | 1.4M | 27.96 |
|
| Adc Therapeutics Sa Comm (ADCT) | 1.3 | $40M | +719% | 11M | 3.53 |
|
| Lb Pharmaceuticals Comm (LBRX) | 1.3 | $39M | 1.7M | 22.26 |
|
|
| Xencor Comm (XNCR) | 1.2 | $38M | 2.5M | 15.31 |
|
|
| Revolution Medicines Comm (RVMD) | 1.2 | $35M | 437k | 79.65 |
|
|
| Agios Pharmaceuticals Comm (AGIO) | 1.1 | $32M | -17% | 1.2M | 27.22 |
|
| Arvinas Holding Comm (ARVN) | 1.0 | $32M | +64% | 2.7M | 11.86 |
|
| Relay Therapeutics Comm (RLAY) | 0.9 | $27M | +77% | 3.2M | 8.46 |
|
| Janux Therapeutics Comm (JANX) | 0.8 | $25M | NEW | 1.8M | 13.80 |
|
| Entrada Therapeutics Comm (TRDA) | 0.7 | $22M | +257% | 2.1M | 10.28 |
|
| Mbx Biosciences Comm (MBX) | 0.7 | $21M | 650k | 31.54 |
|
|
| Upstream Bio Comm (UPB) | 0.7 | $20M | -64% | 744k | 27.15 |
|
| Silence Therapeutics Adrs (SLN) | 0.6 | $18M | 3.0M | 6.08 |
|
|
| Urogen Pharma Comm (URGN) | 0.6 | $17M | 717k | 23.42 |
|
|
| Alector Comm (ALEC) | 0.5 | $16M | NEW | 10M | 1.56 |
|
| Monopar Therapeutics Comm (MNPR) | 0.3 | $9.3M | -7% | 142k | 65.30 |
|
| Avalo Therapeutics Comm (AVTX) | 0.3 | $8.8M | 483k | 18.16 |
|
|
| Maze Therapeutics Comm (MAZE) | 0.2 | $7.2M | NEW | 174k | 41.43 |
|
| Mirum Pharmaceuticals Comm (MIRM) | 0.2 | $4.9M | NEW | 62k | 78.99 |
|
| Athira Pharma Comm | 0.1 | $3.3M | NEW | 464k | 7.21 |
|
| Korro Bio Comm (KRRO) | 0.1 | $3.3M | 416k | 8.01 |
|
|
| Ventyx Biosciences Comm (VTYX) | 0.1 | $2.9M | 316k | 9.03 |
|
|
| Vistagen Therapeutics Comm (VTGN) | 0.1 | $1.8M | 2.7M | 0.66 |
|
Past Filings by TCG Crossover Management
SEC 13F filings are viewable for TCG Crossover Management going back to 2021
- TCG Crossover Management 2025 Q4 filed Feb. 17, 2026
- TCG Crossover Management 2025 Q3 filed Nov. 17, 2025
- TCG Crossover Management 2025 Q2 filed Aug. 14, 2025
- TCG Crossover Management 2025 Q1 filed May 14, 2025
- TCG Crossover Management 2024 Q4 filed Feb. 14, 2025
- TCG Crossover Management 2024 Q3 filed Nov. 14, 2024
- TCG Crossover Management 2024 Q2 filed Aug. 14, 2024
- TCG Crossover Management 2024 Q1 filed May 15, 2024
- TCG Crossover Management 2023 Q4 filed Feb. 14, 2024
- TCG Crossover Management 2023 Q3 filed Nov. 14, 2023
- TCG Crossover Management 2023 Q2 filed Aug. 14, 2023
- TCG Crossover Management 2023 Q1 filed May 15, 2023
- TCG Crossover Management 2022 Q4 filed Feb. 14, 2023
- TCG Crossover Management 2022 Q3 filed Nov. 14, 2022
- TCG Crossover Management 2022 Q2 filed Aug. 15, 2022
- TCG Crossover Management 2022 Q1 filed May 16, 2022